X4 Pharmaceuticals (XFOR): Q3 net product sales rose to $2.8M from $1.6M a year earlier
Q3 revenue $106K vs $199K y/y; nine-month revenue $6.8M vs $28.3M, driven by prior-year license milestone; XOLREMDI sales up to $2.8M.
What this filing says
X4 Pharmaceuticals reported revenue from XOLREMDI sales in the U.S. and mavorixafor licensing and sales outside the U.S. for the quarter ended September 30, 2026. Quarterly product revenue grew year over year as more patients were prescribed the drug, while the filing also notes the company cannot market mavorixafor in new countries until regulators approve it. For a shareholder, the figures show growing sales but also continued dependence on regulatory approvals that the filing describes as complex and uncertain.
Key figures
- Q3 net product sales
- $2.8 million
- Prior-year Q3 net product sales
- $1.6 million
- Nine-month net product sales
- $7.6 million
- Gross-to-net adjustments
- approximately 9% of gross revenues
- Nine-month license revenue from regulatory milestone
- $5.5 million
Positive for shareholders
- Net product sales grew for both the quarter and the nine months, driven by more prescribed patients.
- A regulatory milestone under the Norgine agreement contributed $5.5 million of license revenue in the first nine months of 2026.
Negative for shareholders
- Total license and other revenue fell sharply, from $28.3 million in the first nine months of 2025 to $6.8 million in 2026.
- Mavorixafor cannot be marketed in the U.S. or other countries until the relevant regulator approves it, and the filing warns that approval may be delayed or refused.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- NDA:
- New Drug Application, the request filed with the FDA asking permission to market a new drug in the United States.
- Gross-to-net adjustments:
- Deductions from a drug's list-price sales, such as co-pay assistance and government rebates, that reduce the net revenue a company actually keeps.
- Complete Response Letter:
- An FDA letter stating that a marketing application cannot be approved in its current form and listing what is still needed.
FAQ
How much net product revenue did X4 Pharmaceuticals report for the third quarter of 2026?
The filing reports net product sales of $2.8 million for the three months ended September 30, 2026, up from $1.6 million in the same period of 2025.
Why did X4 Pharmaceuticals' license and other revenue decline?
The filing shows nine-month license revenue of $28.3 million in 2025 was largely a one-time license delivery, while 2026 license revenue was $6.8 million, including a $5.5 million regulatory milestone payment.
Historical context for XFOR
Across the 28 sessions after earlier XFOR headlines, the stock closed higher 17 times and lower 10 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | XFOR | SPY |
|---|---|---|---|
| Nov 4, 2026 | X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 | +2.2% | +1.7% |
| Oct 30, 2026 | X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day | -0.3% | -1.8% |
| Oct 9, 2026 | X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders | +4.3% | +0.6% |
| Oct 8, 2026 | X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures | -0.7% | -0.4% |
| Oct 2, 2026 | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +0.0% | +0.7% |
| Sep 9, 2026 | X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference | +2.7% | -0.5% |
Keep researching XFOR
- XFOR financial statementsRevenue, profit, cash flow and balance sheet from X4 Pharmaceuticals Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- XFOR insider tradesEvery buy and sale reported by X4 Pharmaceuticals Inc. officers, directors and large holders.
- XFOR earnings historyPast X4 Pharmaceuticals Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2017
Follow XFOR and get a push notification the moment its next story breaks.